Personalized Nutrition in Glaucoma: Nutrigenomic Interactions with Macronutrient Metabolism

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/personalized-nutrition-in-glaucoma-nutrigenomic-interactions-with-macronutrient-metabolismTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a group of eye diseases that damage the optic nerve and can lead to vision loss if not treated. High intraocular pressure (IOP) – the fluid pressure inside the eye – is a major risk factor for glaucoma. Standard treatments (like eye drops and surgery) focus on lowering IOP. But growing research suggests that diet and nutrition may influence glaucoma risk and progression () (). For example, diets rich in vegetables (sources of nitric oxide/nitrates) have been linked to lower glaucoma risk () (). Personalized nutrition (or precision nutrition) is the idea of tailoring a person’s diet to their unique biology, including their genes and metabolism. The new field of nutrigenomics studies how genetic differences affect the way our bodies process nutrients (like fats and carbohydrates) and how these interactions impact health. In glaucoma, nutrigenomics could one day help us recommend the best balance of fats, carbohydrates, and proteins for each patient, based on their genes. This article explores how key genes involved in fat and carbohydrate metabolism (notably APOE, PPAR family genes, FADS, and NOS3) might guide personalized diets for glaucoma; how clinical trials could test such approaches; and what ethical and practical issues arise. Genes and Macronutrient Metabolism Certain genes play major roles in determining how our bodies handle fats and carbohydrates. Variants (different versions) of these genes can change metabolic pathways. In the context of glaucoma, several genes are of interest: APOE (Apolipoprotein E) – This gene makes a protein that transports cholesterol and fats in the body, especially in the brain and retina (). There are three common APOE variants (called ε2, ε3, ε4). People with the ε4 version tend to have higher blood cholesterol levels. In general nutrition science, APOE4 carriers often show larger cholesterol changes when they change their intake of saturated fats (). (For example, cutting saturated fat often lowers cholesterol more in APOE4 individuals than in others.) In glaucoma research, some studies even suggest APOE4 might protect the optic nerve from damage (), though the picture is complex. From a diet viewpoint, an APOE4 carrier might benefit especially from a low saturated-fat diet and increased healthy fats (in line with heart-healthy guidelines). PPARs (Peroxisome Proliferator-Activated Receptors) – These genes (especially PPARα and PPARγ) are regulators that turn on or off pathways controlling fat and sugar metabolism. The PPARγ gene has a well-studied variant called Pro12Ala. People carrying the “Ala12” variant often have greater sensitivity to different types of fat in the diet. For instance, one trial found that carriers of PPARγ Ala12 lowered their cholesterol and triglyceride levels more when their diet had a higher ratio of unsaturated fats (polyunsaturated/saturated fat) (). Another study showed that Ala12 carriers lost more weight on a Mediterranean-style diet rich in olive oil (a monounsaturated fat) than on a standard low-fat diet (). In short, PPAR variants influence how well someone responds to healthy (unsaturated) versus less healthy fats. For glaucoma patients with these PPAR variants, emphasizing omega-3 and monounsaturated fats (from fish, nuts, and olive oil) over saturated fats may be parSupport the show